Hepatic Cirrhosis Clinical Trial
Official title:
A Multi-centre, Multi-national Open Study in Patients With Hepatic Cirrhosis to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.
This is a multi-centre, multi-national, open study to assess the pharmacokinetics of NRL972 in patients with hepatic cirrhosis CTP-classes A, B, and C (histologically confirmed by liver biopsy). The pharmacokinetics of NRL972 will be referenced to a Clinical Staging Matrix obtained during a clinical work-up of patients with hepatic cirrhosis. Patients to be studied will have histologically established hepatic cirrhosis or confirmed hepatic cirrhosis by an objective imaging study without confounding end-stage co-morbidity. Within 14 days of confirming eligibility, the investigations will be conducted over 2-5 days with the test procedures (clinical laboratory tests, ultrasound (US)-investigations, gastroscopy, NRL972- and MEGX'-test). Up to one week after the NRL972-test, a follow-up telephone call will be made.
Status | Completed |
Enrollment | 1200 |
Est. completion date | June 2009 |
Est. primary completion date | June 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: Subjects meeting the following conditions will be eligible for enrolment: - Patient has given his or her written informed consent to the study participation, prior to study specific procedures - Male and female (non-child-bearing potential = post-menopausal or medically adequate contraception) - Ethnicity: any - Age: 18 to 80 years of age - Patients with histologically established diagnosis of hepatic cirrhosis and available histological material for review by the central histopathologist or a CTP score greater than or equal to 10 points plus an objective imaging study (CT or NMR scan) within 3 months of the screening visit with a confirmation of hepatic cirrhosis (scans are collected and reviewed), but excluding patients with the diagnosis of primary biliary cirrhosis, primary sclerosing cholangitis and cystic fibrosis-associated liver disease - Present CTP-class A, B or C - Medically fit to undergo the protocol-defined procedures without undue risk and discomfort - Predicted life-expectancy greater than or equal to 6 months by clinical judgement Exclusion Criteria: Subjects of any of the following categories will be excluded from enrolment: - Previous participation in this trial (except for scheduled re-testing in relation to technical difficulties with initial test) - Participant in any other trial during the last 90 days - Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL within the last 3 months - Any donation of germ cells, blood, organs, or bone marrow during the course of the study - History of any clinically relevant allergy (including hypersensitivity to the trial medications) - Presence of clinical relevant acute or chronic infection (other than chronic viral hepatitis, if applicable) - Use of confounding concomitant medication - Presence or history of any end-stage (co-)morbidity (excluding the effects of hepatic cirrhosis) such as: malignancy and clinically relevant systemic diseases - Suspicion or evidence that the subject is not trustworthy and reliable - Suspicion or evidence that the subject is not able to make a free consent or to understand the information in this regard - Primary biliary cirrhosis and primary sclerosing cholangitis - Cystic fibrosis - Previous liver transplantation or intended liver transplantation within 6 months after enrolment - Patients having undergone previous transjugular intrahepatic portosystemic shunt (TIPS) or portocaval anastomosis (PCA) - Patients who are employees at the investigational site, relatives or spouses of the investigator - Current drug, or medication abuse Special restrictions for female patients: - Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation. - Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, unless they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels greater than 40 mIU/m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or hysterectomy or are using one or more of the following acceptable methods of contraception: surgical sterilization (e.g., bilateral tubal ligation, vasectomy), hormonal contraception (implantable, patch, oral), and double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap) |
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
Germany | University Hospital | Essen |
Lead Sponsor | Collaborator |
---|---|
Norgine |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Influence of CTP staging on the pharmacokinetics of NRL972 in patients with cirrhosis. | Single dose, 2-5 day follow-up | No | |
Secondary | Inter-subject relationship between the pharmacokinetics of NRL972 and other parameters used to define the severity of hepatic cirrhosis | 2-5 days | No | |
Secondary | To assess the safety and tolerability of 2mg NRL972 administered by intravenous injection to patients with hepatic cirrhosis | 2-5 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01349348 -
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
|
Phase 3 | |
Active, not recruiting |
NCT04682847 -
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
|
||
Recruiting |
NCT05904470 -
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
|
Phase 2 | |
Completed |
NCT02138253 -
A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
|
Phase 2 | |
Recruiting |
NCT02652351 -
Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis
|
Phase 1 | |
Completed |
NCT00856713 -
Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02163512 -
Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites
|
||
Completed |
NCT00857480 -
Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin
|
Phase 1 | |
Completed |
NCT00006164 -
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
|
Phase 3 | |
Completed |
NCT03486912 -
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
|
Phase 2 | |
Completed |
NCT00698464 -
Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
|
Phase 1 | |
Completed |
NCT02778425 -
The Treatment of Hepatocirrhosis and Portal Hypertension
|
N/A | |
Completed |
NCT03445208 -
A Study of Experimental Medication BMS-986036 Given to Healthy Participants
|
Phase 1 | |
Completed |
NCT03420768 -
A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C
|
Phase 2 | |
Completed |
NCT03804593 -
HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)
|
||
Completed |
NCT03712280 -
MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)
|
Phase 2 | |
Completed |
NCT02230670 -
A Study of IDN-6556 in Subjects With Liver Cirrhosis
|
Phase 2 | |
Completed |
NCT02230683 -
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
|
Phase 2 | |
Completed |
NCT01135628 -
Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy
|
N/A | |
Completed |
NCT00856869 -
Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers
|
Phase 1/Phase 2 |